The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) closed the day trading at $33.66 up 3.57% from the previous closing price of $32.50. In other words, the price has increased by $3.57 from its previous closing price. On the day, 0.86 million shares were traded. AGIO stock price reached its highest trading level at $34.58 during the session, while it also had its lowest trading level at $32.53.
Ratios:
For a better understanding of AGIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.99 and its Current Ratio is at 12.27. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On February 03, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $41.
Goldman Upgraded its Sell to Neutral on November 17, 2022, whereas the target price for the stock was revised from $17 to $32.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 10 ’24 when FOUSE JACQUALYN A sold 7,791 shares for $27.55 per share. The transaction valued at 214,642 led to the insider holds 137,396 shares of the business.
Foster-Cheek Kaye I sold 1,285 shares of AGIO for $40,632 on Mar 07 ’24. The Director now owns 5,524 shares after completing the transaction at $31.62 per share. On Mar 06 ’24, another insider, Foster-Cheek Kaye I, who serves as the Director of the company, sold 4,415 shares for $31.99 each. As a result, the insider received 141,236 and left with 6,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1910979200 and an Enterprise Value of 1186586496. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.25 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 44.238 whereas that against EBITDA is -3.083.
Stock Price History:
Over the past 52 weeks, AGIO has reached a high of $35.50, while it has fallen to a 52-week low of $19.80. The 50-Day Moving Average of the stock is 11.09%, while the 200-Day Moving Average is calculated to be 31.42%.
Shares Statistics:
Over the past 3-months, AGIO traded about 753.53K shares per day on average, while over the past 10 days, AGIO traded about 742200 shares per day. A total of 55.95M shares are outstanding, with a floating share count of 55.30M. Insiders hold about 2.59% of the company’s shares, while institutions hold 105.82% stake in the company. Shares short for AGIO as of 1713139200 were 6653774 with a Short Ratio of 8.83, compared to 1710460800 on 6850350. Therefore, it implies a Short% of Shares Outstanding of 6653774 and a Short% of Float of 11.9799994.
Earnings Estimates
The stock of Agios Pharmaceuticals Inc (AGIO) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$1.65 for the current quarter, with a high estimate of -$1.53 and a low estimate of -$1.78, while EPS last year was -$1.47. The consensus estimate for the next quarter is -$1.66, with high estimates of -$1.46 and low estimates of -$1.82.
Analysts are recommending an EPS of between -$3.03 and -$7.13 for the fiscal current year, implying an average EPS of -$5.81. EPS for the following year is -$5.89, with 9.0 analysts recommending between -$3.14 and -$8.8.
Revenue Estimates
9 analysts predict $8.37M in revenue for the current quarter. It ranges from a high estimate of $10M to a low estimate of $7.1M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $5.61MFor the next quarter, 9 analysts are estimating revenue of $9.51M. There is a high estimate of $14.91M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $59.74M, while the lowest revenue estimate was $31M, resulting in an average revenue estimate of $42.28M. In the same quarter a year ago, actual revenue was $26.82MBased on 9 analysts’ estimates, the company’s revenue will be $113.7M in the next fiscal year. The high estimate is $273M and the low estimate is $65.4M.
